Specifica

Specifica operates as a specialized antibody discovery platform and services company within the broader contract research organization IQVIA. Its core offering is the Generation 3 antibody library platform, which is designed to yield antibodies with exceptional affinity, diversity, and developability profiles, comparable to marketed therapeutics. The company provides these libraries as exclusive assets to partners and also offers full platform transfers, custom library design, and fee-for-service R&D support. By focusing on delivering high-quality, drug-like antibody leads and data packages for AI training, Specifica positions itself as an enabler for biopharma companies and AI-driven drug discovery efforts.

Generation 3 synthetic antibody libraries combined with the AbXtract bioinformatics platform for machine learning-driven analysis and clustering. Designed to yield antibodies with high affinity, diversity, and superior developability profiles from the outset of discovery.

Specifica competes in the antibody discovery platform space against established library technology firms, transgenic animal platform companies, and a new wave of AI/ML-driven antibody design startups. Its key differentiators are its claims of exceptional developability rates, exclusive library assets, and the ability to provide full platform transfers backed by the resources of IQVIA.